Daily Cardiology Research Analysis
Three standout cardiology studies emerged: (1) Endothelial IGFBP6 was identified as a homeostatic brake on vascular inflammation and atherosclerosis through an MVP–JNK/NF-κB axis with protective effects in mice. (2) A small-molecule ERBB4 activator (EF-1) reduced cardiomyocyte injury and cardiac fibrosis across preclinical models, suggesting a new therapeutic class for heart failure. (3) An AI deep neural network distinguished congenital LQTS from acquired QT prolongation on 12-lead ECGs with AU
Summary
Three standout cardiology studies emerged: (1) Endothelial IGFBP6 was identified as a homeostatic brake on vascular inflammation and atherosclerosis through an MVP–JNK/NF-κB axis with protective effects in mice. (2) A small-molecule ERBB4 activator (EF-1) reduced cardiomyocyte injury and cardiac fibrosis across preclinical models, suggesting a new therapeutic class for heart failure. (3) An AI deep neural network distinguished congenital LQTS from acquired QT prolongation on 12-lead ECGs with AUC ~0.90, enabling scalable genetic disease screening.
Research Themes
- Vascular inflammation and atherosclerosis mechanisms
- Novel small-molecule cardioprotective signaling (ERBB4)
- AI-enabled genetic arrhythmia detection from ECG
Selected Articles
1. Endothelial IGFBP6 suppresses vascular inflammation and atherosclerosis.
IGFBP6 acts as an endothelial homeostatic mediator that dampens inflammatory signaling and monocyte adhesion via an MVP–JNK/NF-κB pathway. Human, cellular, and mouse data converge to show that loss of IGFBP6 predisposes to atherosclerosis, whereas endothelial overexpression is protective, nominating IGFBP6 as a potential therapeutic target.
Impact: This work uncovers a previously unrecognized endothelial brake on vascular inflammation with clear mechanistic elucidation and in vivo validation, directly linking basic biology to atherosclerosis pathogenesis.
Clinical Implications: IGFBP6 augmentation or mimetics could represent a novel anti-inflammatory strategy for atherosclerosis beyond lipid-lowering, and circulating IGFBP6 might serve as a biomarker of vascular inflammatory risk.
Key Findings
- IGFBP6 is reduced in human atherosclerotic arteries and patient serum.
- Endothelial IGFBP6 knockdown increases inflammatory gene expression and monocyte adhesion; overexpression reverses TNF and disturbed-flow effects.
- Anti-inflammatory effects operate via MVP–JNK/NF-κB signaling.
- IGFBP6-deficient mice develop aggravated diet- and disturbed-flow-induced atherosclerosis, while endothelial IGFBP6 overexpression is protective.
Methodological Strengths
- Multi-tiered evidence: human tissue/serum, cellular perturbation, and complementary mouse genetic models.
- Mechanistic dissection identifying the MVP–JNK/NF-κB axis.
Limitations
- Preclinical study without interventional human trials; translational dosing and delivery of IGFBP6 remain unknown.
- Potential off-target or context-specific effects of IGFBP6 modulation not fully explored.
Future Directions: Develop IGFBP6-based therapeutics (protein, gene therapy, or small-molecule upregulators), validate circulating IGFBP6 as a biomarker, and assess efficacy/safety in large animal models and early-phase trials.
Beyond dyslipidemia, inflammation contributes to the development of atherosclerosis. However, intrinsic factors that counteract vascular inflammation and atherosclerosis remain scarce. Here we identify insulin-like growth factor binding protein 6 (IGFBP6) as a homeostasis-associated molecule that restrains endothelial inflammation and atherosclerosis. IGFBP6 levels are significantly reduced in human atherosclerotic arteries and patient serum. Reduction of IGFBP6 in human endothelial cells by siRNA increases inflammatory molecule expression and monocyte adhesion. Conversely, pro-inflammatory effects mediated by disturbed flow (DF) and tumor necrosis factor (TNF) are reversed by IGFBP6 overexpression. Mechanistic investigations further reveal that IGFBP6 executes anti-inflammatory effects directly through the major vault protein (MVP)-c-Jun N-terminal kinase (JNK)/nuclear factor kappa B (NF-κB) signaling axis. Finally, IGFBP6-deficient mice show aggravated diet- and DF-induced atherosclerosis, whereas endothelial-cell-specific IGFBP6-overexpressing mice protect against atherosclerosis. Based on these findings, we propose that reduction of endothelial IGFBP6 is a predisposing factor in vascular inflammation and atherosclerosis, which can be therapeutically targeted.
2. Small-molecule-induced ERBB4 activation to treat heart failure.
A high-throughput screen identified EF-1, a small-molecule ERBB4 activator that reduces cardiomyocyte injury and cardiac fibrosis via ERBB4-dependent mechanisms. EF-1 conferred protection in angiotensin II, doxorubicin, and myocardial infarction models (sex- and context-dependent), establishing feasibility for a new therapeutic class.
Impact: Demonstrates, for the first time, drug-like small-molecule activation of ERBB4 with functional cardioprotective effects across models, addressing limitations of recombinant ligand therapy.
Clinical Implications: ERBB4 agonists could emerge as antifibrotic and cardioprotective therapies for heart failure and chemotherapy-induced cardiomyopathy; translational work is needed to define safety, pharmacokinetics, and patient selection.
Key Findings
- Screening of 10,240 compounds yielded eight ERBB4-activating chemotypes (EF-1–EF-8), with EF-1 most potent for ERBB4 dimerization.
- EF-1 reduced cardiomyocyte death and hypertrophy and decreased fibroblast collagen production in an ERBB4-dependent manner.
- In vivo, EF-1 inhibited angiotensin II–induced cardiac fibrosis (both sexes) and reduced doxorubicin- and MI-induced damage in females; effects were absent in Erbb4-null mice.
Methodological Strengths
- High-throughput target-focused discovery linked to functional cellular assays and multiple in vivo disease models.
- Genetic dependency validated via Erbb4-null mice confirming on-target mechanism.
Limitations
- Entirely preclinical; human safety, pharmacokinetics, and dose–response remain unknown.
- Sex- and model-dependent efficacy requires mechanistic clarification and broader validation.
Future Directions: Lead optimization for potency/selectivity, ADME/tox profiling, large-animal efficacy, and phase 1 studies; explore combination with standard heart failure therapies and stratification by sex and etiology.
Heart failure is a common and deadly disease requiring new treatments. The neuregulin-1/ERBB4 pathway offers cardioprotective benefits, but using recombinant neuregulin-1 as therapy has limitations due to the need for intravenous delivery and lack of receptor specificity. We hypothesize that small-molecule activation of ERBB4 could protect against heart damage and fibrosis. To test this, we conduct a screening of 10,240 compounds and identify eight structurally similar ones (EF-1 to EF-8) that induce ERBB4 dimerization, with EF-1 being the most effective. EF-1 reduces cell death and hypertrophy in cardiomyocytes and decreases collagen production in cardiac fibroblasts in an ERBB4-dependent manner. In wild-type mice, EF-1 inhibits angiotensin-II-induced fibrosis in males and females and reduces heart damage caused by doxorubicin and myocardial infarction in females, but not in Erbb4-null mice. This study shows that small-molecule ERBB4 activation is feasible and may lead to a novel class of drugs for treating heart failure.
3. Deep Neural Network Analysis of the 12-Lead Electrocardiogram Distinguishes Patients With Congenital Long QT Syndrome From Patients With Acquired QT Prolongation.
Using >2.5 million ECGs for controls and genetically confirmed LQTS cases, a convolutional DNN distinguished congenital LQTS from acquired QT prolongation with AUC 0.896 and strong robustness across settings. This AI tool can triage prolonged-QTc patients toward genetic evaluation and targeted management.
Impact: Delivers a clinically actionable AI that addresses a common diagnostic dilemma—discriminating genetic LQTS from acquired QT prolongation—at scale from routine ECG.
Clinical Implications: Supports screening and prioritization for genetic testing, informs beta-blocker initiation and avoidance of QT-prolonging drugs, and may reduce sudden death risk through earlier identification of congenital LQTS.
Key Findings
- Convolutional DNN achieved AUC 0.896 (accuracy 85%, sensitivity 77%, specificity 87%) distinguishing congenital LQTS from acquired QT prolongation.
- Performance remained robust (AUC ~0.9) across matching ratios (1:5 to 1:2000), ECG data types, and after excluding wide QRS or paced rhythms.
- Training leveraged 808 genetically confirmed LQTS patients with high-QTc ECGs and a massive control pool (361,069 individuals with high-QTc ECGs from 2.5M).
Methodological Strengths
- Large-scale dataset with genetically confirmed cases and rigorous age/sex matching.
- Robust validation across multiple matching ratios and ECG input formats.
Limitations
- Retrospective single-system development; prospective and external multi-system validation needed.
- Black-box interpretability and potential demographic/measurement biases require further study.
Future Directions: Prospective clinical impact studies, integration into ECG workflows for real-time triage, external validations, and explainability tools to guide clinician trust and adoption.
OBJECTIVE: To test whether an artificial intelligence (AI) deep neural network (DNN)-derived analysis of the 12-lead electrocardiogram (ECG) can distinguish patients with long QT syndrome (LQTS) from those with acquired QT prolongation. METHODS: The study cohort included all patients with genetically confirmed LQTS evaluated in the Windland Smith Rice Genetic Heart Rhythm Clinic and controls from Mayo Clinic's ECG data vault comprising more than 2.5 million patients. For the AI-DNN model, every patient and control with 1 or more ECGs above age- and sex-specific 99th percentile values for QTc (>460 ms for all patients [male/female] <13 years of age or >470 ms for men and >480 ms for women above this age) were included. LQTS patients were age and sex matched to controls at a 1:5 ratio. An AI-DNN involving a multilayer convolutional neural network was developed to classify patients. RESULTS: Of the 1,599 patients with genetically confirmed LQTS, 808 had 1 or more ECGs with QTc above the defined thresholds (2987 ECGs) compared with 361,069 of 2.5 million controls (14% of Mayo Clinic patients having an ECG, "presumed negative"; 989,313 ECGs). Following age and sex matching and splitting, 3,309 (training), 411 (validation), and 887 (testing) ECGs were used. This model distinguished patients with LQTS from those with acquired QT prolongation with an area under the curve of 0.896 (accuracy 85%, sensitivity 77%, specificity 87%). The model remained robust with areas under the curve close to or above 0.9, independent of matching ratio (range, 1:5 to 1:2000) or type of ECG data used (rhythm strip of median beat) and after excluding patients with wide QRS or ventricular pacemaker. CONCLUSION: For patients with a QTc exceeding its 99th percentile values, this novel AI-DNN functions as an LQTS mutation detector, being able to identify patients with abnormal QT prolongation secondary to an LQTS-causative mutation rather than with acquired QT prolongation. This algorithm may facilitate screening for this potentially lethal yet highly treatable genetic heart disease.